Skip to main content
TipRanks
Go Ultimate75% OFF

Corcept Therapeutics (0I3Q) Share Price & Analysis

2 Followers

0I3Q Stock Chart & Stats

$70.32$1.07(1.55%)
At close: 4:30 PM GMT
$75$100$125Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$68.50 - $71.57
52-Week Range
$28.67 - $126.57
Previous Close
$69.25
Volume
N/A
Average Volume (3M)
708
Market Cap
$7.58B
Enterprise Value
$13.83B
Total Cash (Recent Filing)
$370.70M
Total Debt (Recent Filing)
$8.99M
Price to Earnings (P/E)
46.3
Beta
-0.58
Next Earnings
Mar 02, 2027 (Est.)
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth And Product Adoption

Rapid growth across the established endocrinology business and newly launched Lifyorli indicates expanding commercial reach and demand. Increasing physician and patient adoption can support durable revenue gains as Corcept broadens its presence across endocrine and oncology markets.

Strong Cash Generation And Conservative Leverage

Robust free cash flow near net income, combined with minimal leverage, gives Corcept substantial financial flexibility. This supports continued investment in clinical development and commercialization while reducing refinancing pressure and the need to rely on external capital.

Broad Pipeline And Expanding Treatment Opportunities

Multiple programs across endocrinology, oncology, liver disease and ALS create opportunities to diversify beyond the current marketed portfolio. Advancing studies and planned trials could expand the addressable market and provide additional long-term growth drivers.

Bears Say

Operating Margin Compression

Lower operating profitability suggests that expenses or nonrecurring impacts are absorbing more of Corcept’s revenue growth. If this persists, earnings may scale less efficiently, limiting the benefit of strong sales momentum and reducing funds available for reinvestment.

Regulatory Uncertainty For Relacorilant

The prior complete response letter demonstrates that relacorilant’s approval path has encountered regulatory obstacles. Until the FDA review is resolved, the timing and commercial contribution of a potentially important Cushing’s and oncology growth driver remain uncertain.

Underdiagnosis Limits Market Expansion

Persistent underdiagnosis can constrain the number of patients identified and treated, even when clinical evidence and screening recommendations improve. Slow adoption of updated standards may therefore lengthen the time needed to convert disease awareness into durable demand.

Corcept Therapeutics News

0I3Q FAQ

What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest share price was $28.67 and its highest was $126.57 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $7.58B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 104 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Nov 03, 2026. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.17.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Corcept Therapeutics dividends here
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 1.12.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 109,443,110 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of $1.01 in its last earnings report, beating expectations of $0.84. Following the earnings report the stock price went down -7.093%.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Hedge funds hold Corcept Therapeutics shares: the largest hedge-fund position in Corcept Therapeutics is 1,986,764,094 shares, and hedge funds increased their holdings by 239.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology